Furosemide
- Generic Name
- Furosemide
- Brand Names
- Furoscix, Lasix
- Drug Type
- Small Molecule
- Chemical Formula
- C12H11ClN2O5S
- CAS Number
- 54-31-9
- Unique Ingredient Identifier
- 7LXU5N7ZO5
- Background
Furosemide is a potent loop diuretic that acts on the kidneys to ultimately increase water loss from the body. It is an anthranilic acid derivative. Furosemide is used for edema secondary to various clinical conditions, such as congestive heart failure exacerbation, liver failure, renal failure, and high blood pressure. It mainly works by inhibiting electrol...
- Indication
Furosemide is indicated for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome, in adults and pediatric patients.
...
- Associated Conditions
- Acute Pulmonary Edema, Ascites, Body Fluid Retention, Edema, Hypertension, Mild to Moderate Hypertension, Chest congestion
- Associated Therapies
- -
The Impact of TORasemide oN hemodynAmic and Neurohormonal Stress, and carDiac remOdeling in Heart Failure
- First Posted Date
- 2013-09-13
- Last Posted Date
- 2017-06-08
- Lead Sponsor
- Medical University of Warsaw
- Target Recruit Count
- 100
- Registration Number
- NCT01942109
- Locations
- 🇵🇱
3rd Clinic of Internal Medicine and Cardiology of Medcial University of Warsaw, Warsaw, Mazowieckie, Poland
🇵🇱1st Department of Cariology of Medcial University of Warsaw, Warsaw, Mazowieckie, Poland
Diuretics and Dopamine in Heart Failure With Preserved Ejection Fraction
- First Posted Date
- 2013-07-17
- Last Posted Date
- 2018-08-16
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 90
- Registration Number
- NCT01901809
- Locations
- 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
Inhaled Nebulized Furosemide & Physical Activity-Related Breathlessness
- First Posted Date
- 2013-05-13
- Last Posted Date
- 2017-02-14
- Lead Sponsor
- McGill University
- Target Recruit Count
- 30
- Registration Number
- NCT01851980
- Locations
- 🇨🇦
Centre of Innovative Medicine of the McGill University Health Centre, Montreal, Quebec, Canada
Pharmacokinetic Profile and Pharmacodynamic Characteristics of a Furosemide High Dosage Formulation in Patients With Chronic Renal Failure Undergoing Peritoneal Dialysis
- First Posted Date
- 2012-11-12
- Last Posted Date
- 2013-02-12
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 12
- Registration Number
- NCT01724788
- Locations
- 🇨🇦
Investigational Site Number 124002, Montreal, Canada
Peritoneal Dialysis vs Furosemide for Acute Kidney Injury After Cardiopulmonary Bypass
- Conditions
- Interventions
- First Posted Date
- 2012-10-18
- Last Posted Date
- 2017-06-09
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 73
- Registration Number
- NCT01709227
- Locations
- 🇺🇸
Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio, United States
Furosemide Treatment Before Blood Transfusion in Patients With Systolic Dysfunction
- Conditions
- Interventions
- First Posted Date
- 2012-10-12
- Last Posted Date
- 2016-06-28
- Lead Sponsor
- Tel-Aviv Sourasky Medical Center
- Registration Number
- NCT01705470
Furosemide Versus Ethacrynic Acid in Children With Congenital Heart Disease
- First Posted Date
- 2012-06-27
- Last Posted Date
- 2014-07-24
- Lead Sponsor
- Bambino Gesù Hospital and Research Institute
- Target Recruit Count
- 74
- Registration Number
- NCT01628731
- Locations
- 🇮🇹
Bambino Gesù Hospital, Rome, Italy
Drug to Drug Interaction Study With Ipragliflozin and Furosemide
- Conditions
- Interventions
- First Posted Date
- 2012-06-05
- Last Posted Date
- 2012-06-05
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 24
- Registration Number
- NCT01611415
B-type Natriuretic Peptide as a Surrogate Marker Guiding Post-operative Fluid Off-loading
- First Posted Date
- 2012-04-25
- Last Posted Date
- 2016-05-27
- Lead Sponsor
- Creighton University
- Target Recruit Count
- 50
- Registration Number
- NCT01584518
- Locations
- 🇺🇸
Creighton University Medical Center, Omaha, Nebraska, United States
A Study of MK-7145 in Participants With Renal Insufficiency (Part I) and Heart Failure With Renal Insufficiency (Part II) (MK-7145-011)
- Conditions
- Interventions
- First Posted Date
- 2012-03-20
- Last Posted Date
- 2018-09-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 11
- Registration Number
- NCT01558674
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.